Numab (Series C Extension)

Funding Details
Awarder
Inbox
Date Award
January 09, 2025
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$55,000,000

Company Info
Traction
Acquisition of Numab’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion.
Organizations Involved
Johnson & Johnson
Founders
David Urech
Company Description
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Market
Immunology and Oncology
Location
Horgen, Switzerland
Coinvestors
Cormorant Asset Management, Forbion, HBM Healthcare Investment, Novo Holdings, BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, BlackRock

Links